1-3 of 3
Christine Segeren
Close
Sort by
Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Final Analysis of the HOVON 24 Trial.

Pieter Sonneveld, MD, Bronno van der Holt, MSc, Edo Vellenga, MD, Sandra Croockewit, MD, Gregor Verhoef, MD, Christine Segeren, MD, Henk Lokhorst, MD
Journal: Blood
Blood (2005) 106 (11): 2545.
https://doi.org/10.1182/blood.V106.11.2545.2545
Published: 2005
Journal Articles

Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.

Pieter Sonneveld, Bronno van der Holt, Christine Segeren, Edo Vellenga, Reinier Raymakers, Gregor Verhoef, Ron Schaafsma, Marinus van Oers, Pierre Weijermans, Wim Fibbe, Shulamit Wittebol, Marinus van Marwijk, Douwe Biesma, Joke Baars, Harry Schouten, Petra Westveer, Monique Steijaert, Henk Lokhorst
Journal: Blood
Blood (2004) 104 (11): 948.
https://doi.org/10.1182/blood.V104.11.948.948
Published: 2004
Journal Articles

Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study

Peter Willems, Onno Verhagen, Christine Segeren, Peter Veenhuizen, Jeroen Guikema, Erik Wiemer, Laura Groothuis, Tineke Buitenweg-de Jong, Henriëtte Kok, Andries Bloem, Nico Bos, Edo Vellenga, Ewald Mensink, Pieter Sonneveld, Henk Lokhorst, Ellen van der Schoot, Reinier Raymakers, the Belgium–Dutch Hematology–Oncology Group
Journal: Blood
Blood (2000) 96 (1): 63–70.
https://doi.org/10.1182/blood.V96.1.63
Published: 2000